22. Naslund J , Thyberg J , Tjernberg LO, e t al. Characterization
of stable complexes involving apolipoprotein E and the amyloid P peptide in Alzheimer's disease brain. Neuron 1995;15:
219-228.
23. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E,
dementia, and cortical deposition of P-amyloid protein.
N Engl J Med 1995;333:1242-1247.
24. Ohm TG, Kirca M, Bohl J , Scharnagl H, Gross W, Marz W.
Apolipoprotein E polymorphism influences not only cerebral
senile plaque load but also Alzheimer-type neurofibrillary
tangle formation. Neuroscience 1995;66:583-587.
25. Schmechel DE, Saunders AM, Strittmatter WJ, et al. In- creased amyloid P-peptide deposition in cerebral cortex as a
consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-9653.
26. Kukull WA, Schellenberg GD, Bowen JD, et al. Apolipoprotein E in Alzheimer's disease risk and case detection: a casecontrol study. J Clin Epidemiol (in press).
27. Nee LE, Eldridge R, Sunderland T, et al. Dementia of the
Alzheimer type: clinical and family study of 22 twin pairs.
Neurology 1987;37:359-363.
28. Small GW, Leuchter AF,Mandelkern MA, et al. Clinical,
neuroimaging, and environmental risk differences in
monozygotic female twins appearing discordant for dementia
of the Alzheimer type. Arch Neurol 1993;50:209-219.
29. Breteler MMB, Claus J J , van Duijn CM, Launer LJ, Hofman
A. Epidemiology of Alzheimer's disease. Epidemiol Rev 1992;
14:59-82.
30. Katzman R. Education and the prevalence of dementia and
Alzheimer's disease. Neurology 1993;43:13-20.
31. Henderson VW, Kukull WA, Buckwalter JG, Larson EB.
Left-handedness and the risk of Alzheimer's disease [ab- stract]. SOCNeurosci Abstr 1996;22:15.
32. Kukull WA, Larson EB, Bowen JD, et al. Solvent exposure as
a risk factor for Alzheimer's disease: a case-control study.
Am J Epidemiol 1995;141:1059-1071.
33. Sohel E, Davanipour Z, Sulkava R, et al. Occupations with
exposure to electromagnetic fields: a possible risk factor for
Alzheimer's disease. Am J Epidemiol 1995;142:515-524.
34. Paganini-Hill A, Henderson VW. Estrogen deficiency and
risk of Alzheimer's disease in women. Am J Epidemiol 1994;
140:256-261.
35. Tang M-X. Jacobs D. Stern Y. et al. Effect of oestroeen during ;henopause on risk and age at onset of Alzheiger's disease. Lancet 1996;348:429-432.
36. Morrison A, Resnick S, Corrada M, Zonderman A, Kawas C.
A prospective study of estrogen replacement therapy and the
risk of developing Alzheimer's disease in the Baltimore longitudinal study of aging [abstract]. Neurology 1996;46(suppl
2):A435-A436.
37. Breitner JCS, Gau BA, Welsh KA, et al. Inverse association
of anti-inflammatory treatments and Alzheimer's disease:
initial results of a co-twin control study. Neurology 1994;44:
227-232.
38. Rich JB, Rasmusson DX, Folstein MF, Carson K, Kawas C,
Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-55.
39. Jeandel C, Nicolas MB, Dubois F, Nabet-Belleville F, Penin
F, Cuny G. Lipid peroxidation and free radical scavengers in
Alzheimer's disease. Gerontology 1989;35:275-282.
40. Jaffe RB. The menopause and perimenopausal period. In:
Yen SSC, Jaffe RB, eds. Reproductive endocrinology, 3rd ed.
Philadelphia: WB Saunders, 1991;389-408.
41. Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little, Brown, 1987.
42. Kawata M. Roles of steroid hormones and their receptors in
structural organization in the nervous system. Neurosci Res
1995;24:1-46.
43. Shughrue PJ, Dorsa DM. Estrogen modulates the growthassociated protein GAP-43 (neuromodulin)mRNA in the rat
preoptic area and basal hypothalamus. Neuroendocrinology
1993;57:439-447.
44. Toran-Allerand CD. Organotypic culture of the developing
cerebral cortex and hypothalamus: relevance to sexual differentiation. Psychoneuroendocrinology 1991;16:7-24.
45. Ferreira A, Caceres A. Estrogen-enhanced neurite growth:
evidence for a selective induction of tau and stable microtubules. J Neurosci 1991;11:392-400.
